Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X

In Duk Jung, Sung Jae Shin, Min-Goo Lee, Tae Heung Kang, Hee Dong Han, Seung Jun Lee, Woo Sik Kim, Hong Min Kim, Won Sun Park, Han Wool Kim, Cheol Heui Yun, Eun Kyung Lee, T. C. Wu, Yeong Min Park

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite the potential for stimulation of robust antitumor immunity by dendritic cells (DCs), clinical applications of DC-based immunotherapy are limited by the low potency in generating tumor Ag-specific T cell responses. Therefore, optimal conditions for generating potent immunostimulatory DCs that overcome tolerance and suppression are key factors in DC-based tumor immunotherapy. In this study, we demonstrate that use of the Mycobacterium tuberculosis heat shock protein X (HspX) as an immunoadjuvant in DC-based tumor immunotherapy has significant potential in therapeutics. In particular, the treatment aids the induction of tumor-reactive T cell responses, especially tumor-specific CTLs. The HspX protein induces DC maturation and proinflammatory cytokine production (TNF-a, IL-1b, IL-6, and IFN-b) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways. We employed two models of tumor progression and metastasis to evaluate HspX-stimulated DCs in vivo. The administration of HspX-stimulated DCs increased the activation of naive T cells, effectively polarizing the CD4+ and CD8+ T cells to secrete IFN-g, as well as enhanced the cytotoxicity of splenocytes against HPV-16 E7 (E7)-expressing TC-1 murine tumor cells in therapeutic experimental animals. Moreover, the metastatic capacity of B16-BL6 melanoma cancer cells toward the lungs was remarkably attenuated in mice that received HspX-stimulated DCs. In conclusion, the high therapeutic response rates with tumor-targeted Th1- type T cell immunity as a result of HspX-stimulated DCs in two models suggest that HspX harnesses the exquisite immunological power and specificity of DCs for the treatment of tumors.

Original languageEnglish
Pages (from-to)1233-1245
Number of pages13
JournalJournal of Immunology
Volume193
Issue number3
DOIs
Publication statusPublished - 2014 Aug 1

Fingerprint

Heat-Shock Proteins
Mycobacterium tuberculosis
Cellular Immunity
Dendritic Cells
Vaccines
T-Lymphocytes
Neoplasms
Immunotherapy
Immunity
Therapeutics
Immunologic Adjuvants
Experimental Melanomas
Th1 Cells
Human papillomavirus 16
Interleukin-6
Cytokines
Neoplasm Metastasis
Lung

ASJC Scopus subject areas

  • Immunology

Cite this

Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X. / Jung, In Duk; Shin, Sung Jae; Lee, Min-Goo; Kang, Tae Heung; Han, Hee Dong; Lee, Seung Jun; Kim, Woo Sik; Kim, Hong Min; Park, Won Sun; Kim, Han Wool; Yun, Cheol Heui; Lee, Eun Kyung; Wu, T. C.; Park, Yeong Min.

In: Journal of Immunology, Vol. 193, No. 3, 01.08.2014, p. 1233-1245.

Research output: Contribution to journalArticle

Jung, ID, Shin, SJ, Lee, M-G, Kang, TH, Han, HD, Lee, SJ, Kim, WS, Kim, HM, Park, WS, Kim, HW, Yun, CH, Lee, EK, Wu, TC & Park, YM 2014, 'Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X', Journal of Immunology, vol. 193, no. 3, pp. 1233-1245. https://doi.org/10.4049/jimmunol.1400656
Jung, In Duk ; Shin, Sung Jae ; Lee, Min-Goo ; Kang, Tae Heung ; Han, Hee Dong ; Lee, Seung Jun ; Kim, Woo Sik ; Kim, Hong Min ; Park, Won Sun ; Kim, Han Wool ; Yun, Cheol Heui ; Lee, Eun Kyung ; Wu, T. C. ; Park, Yeong Min. / Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X. In: Journal of Immunology. 2014 ; Vol. 193, No. 3. pp. 1233-1245.
@article{4aa6549f201b4d45a5e7bd7915a3aec8,
title = "Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X",
abstract = "Despite the potential for stimulation of robust antitumor immunity by dendritic cells (DCs), clinical applications of DC-based immunotherapy are limited by the low potency in generating tumor Ag-specific T cell responses. Therefore, optimal conditions for generating potent immunostimulatory DCs that overcome tolerance and suppression are key factors in DC-based tumor immunotherapy. In this study, we demonstrate that use of the Mycobacterium tuberculosis heat shock protein X (HspX) as an immunoadjuvant in DC-based tumor immunotherapy has significant potential in therapeutics. In particular, the treatment aids the induction of tumor-reactive T cell responses, especially tumor-specific CTLs. The HspX protein induces DC maturation and proinflammatory cytokine production (TNF-a, IL-1b, IL-6, and IFN-b) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways. We employed two models of tumor progression and metastasis to evaluate HspX-stimulated DCs in vivo. The administration of HspX-stimulated DCs increased the activation of naive T cells, effectively polarizing the CD4+ and CD8+ T cells to secrete IFN-g, as well as enhanced the cytotoxicity of splenocytes against HPV-16 E7 (E7)-expressing TC-1 murine tumor cells in therapeutic experimental animals. Moreover, the metastatic capacity of B16-BL6 melanoma cancer cells toward the lungs was remarkably attenuated in mice that received HspX-stimulated DCs. In conclusion, the high therapeutic response rates with tumor-targeted Th1- type T cell immunity as a result of HspX-stimulated DCs in two models suggest that HspX harnesses the exquisite immunological power and specificity of DCs for the treatment of tumors.",
author = "Jung, {In Duk} and Shin, {Sung Jae} and Min-Goo Lee and Kang, {Tae Heung} and Han, {Hee Dong} and Lee, {Seung Jun} and Kim, {Woo Sik} and Kim, {Hong Min} and Park, {Won Sun} and Kim, {Han Wool} and Yun, {Cheol Heui} and Lee, {Eun Kyung} and Wu, {T. C.} and Park, {Yeong Min}",
year = "2014",
month = "8",
day = "1",
doi = "10.4049/jimmunol.1400656",
language = "English",
volume = "193",
pages = "1233--1245",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X

AU - Jung, In Duk

AU - Shin, Sung Jae

AU - Lee, Min-Goo

AU - Kang, Tae Heung

AU - Han, Hee Dong

AU - Lee, Seung Jun

AU - Kim, Woo Sik

AU - Kim, Hong Min

AU - Park, Won Sun

AU - Kim, Han Wool

AU - Yun, Cheol Heui

AU - Lee, Eun Kyung

AU - Wu, T. C.

AU - Park, Yeong Min

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Despite the potential for stimulation of robust antitumor immunity by dendritic cells (DCs), clinical applications of DC-based immunotherapy are limited by the low potency in generating tumor Ag-specific T cell responses. Therefore, optimal conditions for generating potent immunostimulatory DCs that overcome tolerance and suppression are key factors in DC-based tumor immunotherapy. In this study, we demonstrate that use of the Mycobacterium tuberculosis heat shock protein X (HspX) as an immunoadjuvant in DC-based tumor immunotherapy has significant potential in therapeutics. In particular, the treatment aids the induction of tumor-reactive T cell responses, especially tumor-specific CTLs. The HspX protein induces DC maturation and proinflammatory cytokine production (TNF-a, IL-1b, IL-6, and IFN-b) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways. We employed two models of tumor progression and metastasis to evaluate HspX-stimulated DCs in vivo. The administration of HspX-stimulated DCs increased the activation of naive T cells, effectively polarizing the CD4+ and CD8+ T cells to secrete IFN-g, as well as enhanced the cytotoxicity of splenocytes against HPV-16 E7 (E7)-expressing TC-1 murine tumor cells in therapeutic experimental animals. Moreover, the metastatic capacity of B16-BL6 melanoma cancer cells toward the lungs was remarkably attenuated in mice that received HspX-stimulated DCs. In conclusion, the high therapeutic response rates with tumor-targeted Th1- type T cell immunity as a result of HspX-stimulated DCs in two models suggest that HspX harnesses the exquisite immunological power and specificity of DCs for the treatment of tumors.

AB - Despite the potential for stimulation of robust antitumor immunity by dendritic cells (DCs), clinical applications of DC-based immunotherapy are limited by the low potency in generating tumor Ag-specific T cell responses. Therefore, optimal conditions for generating potent immunostimulatory DCs that overcome tolerance and suppression are key factors in DC-based tumor immunotherapy. In this study, we demonstrate that use of the Mycobacterium tuberculosis heat shock protein X (HspX) as an immunoadjuvant in DC-based tumor immunotherapy has significant potential in therapeutics. In particular, the treatment aids the induction of tumor-reactive T cell responses, especially tumor-specific CTLs. The HspX protein induces DC maturation and proinflammatory cytokine production (TNF-a, IL-1b, IL-6, and IFN-b) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways. We employed two models of tumor progression and metastasis to evaluate HspX-stimulated DCs in vivo. The administration of HspX-stimulated DCs increased the activation of naive T cells, effectively polarizing the CD4+ and CD8+ T cells to secrete IFN-g, as well as enhanced the cytotoxicity of splenocytes against HPV-16 E7 (E7)-expressing TC-1 murine tumor cells in therapeutic experimental animals. Moreover, the metastatic capacity of B16-BL6 melanoma cancer cells toward the lungs was remarkably attenuated in mice that received HspX-stimulated DCs. In conclusion, the high therapeutic response rates with tumor-targeted Th1- type T cell immunity as a result of HspX-stimulated DCs in two models suggest that HspX harnesses the exquisite immunological power and specificity of DCs for the treatment of tumors.

UR - http://www.scopus.com/inward/record.url?scp=84906074259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906074259&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1400656

DO - 10.4049/jimmunol.1400656

M3 - Article

C2 - 24990079

AN - SCOPUS:84906074259

VL - 193

SP - 1233

EP - 1245

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -